<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-TNC-10000955</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2010-07-24</date_registration>
      <primary_sponsor>People's Hospital, Peking University</primary_sponsor>
      <public_title>Imatinib mesylate versus allogeneic HSCT for patients with chronic myelogenous leukemia</public_title>
      <acronym />
      <scientific_title>Imatinib mesylate versus allogeneic HSCT for patients with chronic myelogenous leukemia</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2001-04-01</date_enrolment>
      <type_enrolment />
      <target_size>A:300;B:300;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=8583</url>
      <study_type>Observational study</study_type>
      <study_design>Non randomized control</study_design>
      <phase>Post-market</phase>
      <hc_freetext>chronic myelogenous leukemia</hc_freetext>
      <i_freetext>A:transplant;B:imatinib;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Qian Jiang</firstname>
        <middlename />
        <lastname />
        <address>11 Xizhimen South Street, Beijing, China</address>
        <city />
        <country1 />
        <zip>100044</zip>
        <telephone>+86 10 88326852</telephone>
        <email>jiangqian@medmail.com.cn</email>
        <affiliation>Institute of Hematology, Peking University and People's Hospital, Peking University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Xiaojun Huang</firstname>
        <middlename />
        <lastname />
        <address>11 Xizhimen South Street, Beijing, China</address>
        <city />
        <country1 />
        <zip>100044</zip>
        <telephone>+86 10 88326006</telephone>
        <email>xjhrm@medmail.com.cn</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with chronic myelogenous leukemia in chronic phase, accelerated phase or blast phase enroll in imatinib group or transplant group by their intention</inclusion_criteria>
      <agemin>10</agemin>
      <agemax>65</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Serious cardiac, pulmonary, hepatic and renal function failure</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F99</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>overall survival;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>progression-free survival;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>National Outstanding Yong Scientists' Foundation of China, Program for Innovative Research Team in University and Beijing Novartis Pharma Co., Ltd., China</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2001-04-24</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>